Angel Therapeutics is a global biotechnology company headquartered in the San Francisco Bay Area. Our mission is to develop competitive innovative biotherapeutics to improve the lives of cancer patients. Our Vision is to become one of the global leading companies in research & development of monoclonal antibody and Fc-fusion protein therapeutics.

At Angel Therapeutics we have pioneered a unique way of discovering and developing biotherapeutics. Our approach is aimed primarily on oncology and immuno-oncology cancer therapeutics– Antibodies. Our discovery platform leverages modern drug discovery technologies and state-of-the-art biologics innovation techniques to identify therapeutic agents that can address unmet medical needs world-wide.

Angel Therapeutics focuses on four therapeutic areas: oncology, bone health, nephrology, and inflammation.

Angel Therapeutics is a global biopharmaceutical company dedicated to discovering and developing to monoclonal antibody and Fc-fusion protein therapeutics and cell therapy-based treatment of cancers.

The company combines expertise in disease biology and protein science to advance its growing pipeline of biologics that are optimized against clinically-validated targets.

Based in the San Francisco Bay Area and Boston – biotechnology hubs, Angel Therapeutics is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in treatment of cancers, globally.

Our Approach

Our approach is focused on oncology and immune-oncology, and next generation of cell therapy.